Protocol for sampling environmental sites for legionellae.

Appl Environ Microbiol

Respiratory Diseases Branch, Center for Infectious Diseases, Atlanta, Georgia 30333.

Published: July 1987

A protocol for sampling environmental sites was developed and used to identify possible sources of Legionella species in support of epidemiologic investigations at two hospitals. In hospital A, legionellae were isolated from 43 of 106 (40%) different sites. Three separate Legionella pneumophila serotypes and a previously unrecognized species were present in different combinations in the positive samples. Two of five cooling towers contained the same L. pneumophila serogroup 1 monoclonal type (1,2,4,5) as was isolated from patients. The same monoclonal type was also isolated from make-up water for the two cooling towers, a hot water tank, water separators in four main air compressor systems for respiratory therapy, and cold and hot water faucets. In hospital B, 13 of 37 (38%) sample sites contained legionellae, all of which were L. pneumophila serogroup 1. The monoclonal type matching isolates from patients (1,2,4,5) was found at the highest concentration in a hot water tank, but it was also present at four other sample sites. Since legionellae not related to disease may be found in many of the sites sampled, an epidemiologic association with the probable source should be established before intervention methods, such as disinfection, are undertaken.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC203891PMC
http://dx.doi.org/10.1128/aem.53.7.1454-1458.1987DOI Listing

Publication Analysis

Top Keywords

monoclonal type
12
hot water
12
protocol sampling
8
sampling environmental
8
environmental sites
8
sites legionellae
8
cooling towers
8
pneumophila serogroup
8
serogroup monoclonal
8
water tank
8

Similar Publications

Proprotein convertase subtilisin/kexin type 9 (PCSK9) discovery has added a new paradigm to our understanding of cholesterol homeostasis and lipid metabolism. Since its discovery, PCSK9 inhibitors have become a widely investigated therapeutic class for lipid management in cardiovascular diseases and hypercholesterolemia. Scientists have explored different approaches for PCSK9 inhibition, such as monoclonal antibodies (mAbs), gene silencing and gene editing techniques, vaccines, mimetic peptides, and small molecules.

View Article and Find Full Text PDF

Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis.

Ital J Dermatol Venerol

January 2025

Department of Dermatology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan (ROC) -

Risankizumab (Skyrizi, Abbvie, North Chicago, IL, USA) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting the p19 subunit of IL-23, thereby inhibiting IL-23-dependent releasing of proinflammatory cytokines in plaque psoriasis. Risankizumab is licensed is most countries for the treatment of patients with moderate-to-severe plaque psoriasis, and in Japan for generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis. Risankizumab showed higher efficacy and favorable safety profiles in patients with moderate-to-severe plaque psoriasis, compared with adalimumab, secukinumab and ustekinumab in several randomized controlled phase 3 pivotal studies and among real-life data in large retrospective studies.

View Article and Find Full Text PDF

Methods based on enzyme labelling strategies have been widely developed for capacitance immunoassays, but most suffer from low sensitivity and are unfavorable for routine use in the early stages of diagnostics. Herein, we designed a highly efficient capacitance immunosensing method for the low-abundance neuroblastoma biomarker neuron-specific enolase (NSE) using an interdigitated micro-comb electrode. Initially, monoclonal mouse anti-human NSE capture antibodies were immobilized on the interdigitated gold electrodes using bovine serum albumin.

View Article and Find Full Text PDF

Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.

Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials.

Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels.

View Article and Find Full Text PDF

Objective: Lowering lipid to reach guideline-indicated goals significantly reduces cardiovascular outcomes in very-high-risk (VHR) patients with atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes (DM2). How well VHR patients currently achieve these goals in community practice is unknown.

Methods: VHR patients with ASCVD and DM2 were identified across 14 US healthcare systems using electronic health records between 1/1/2021-12/31/2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!